Aurinia Pharmaceuticals (AUPH) Total Non-Current Liabilities (2019 - 2024)
Aurinia Pharmaceuticals (AUPH) posted Total Non-Current Liabilities of $162.1 million for Q4 2024, up 7.67% on a QoQ basis from $150.5 million in Q3 2024, and up 1.79% year-over-year from $159.2 million in Q1 2024.
Aurinia Pharmaceuticals (AUPH) Total Non-Current Liabilities (2019 - 2024) Analysis & Trends
Aurinia Pharmaceuticals' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $162.1 million for Q4 2024.
- Quarterly Total Non-Current Liabilities rose 1.79% year-over-year to $162.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $162.1 million (up 1.79% YoY) and the FY2024 annual result came in at $162.1 million, up 1.79% from the prior year.
- Total Non-Current Liabilities was $162.1 million for Q4 2024 at Aurinia Pharmaceuticals, up from $150.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $162.1 million in Q4 2024 and bottomed at $29.0 million in Q1 2021.
- A 5-year average of $88.2 million and a median of $49.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 251.47% — and 2024, when it slipped 1.52%.
- Aurinia Pharmaceuticals' Total Non-Current Liabilities stood at $39.6 million in 2020, then advanced by 21.86% to $48.3 million in 2021, then climbed by 10.25% to $53.2 million in 2022, then soared by 199.12% to $159.2 million in 2023, then climbed by 1.79% to $162.1 million in 2024.
- Business Quant data shows AUPH's Total Non-Current Liabilities at $162.1 million in Q4 2024, $150.5 million in Q3 2024, and $148.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Aurinia Pharmaceuticals | 2.02 Bn | 1.64 Bn | 71.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 162.06 Mn |
| Sep 30, 2024 | 150.52 Mn |
| Jun 30, 2024 | 148.01 Mn |
| Mar 31, 2024 | 144.86 Mn |
| Dec 31, 2023 | 159.21 Mn |
| Sep 30, 2023 | 152.84 Mn |
| Jun 30, 2023 | 147.90 Mn |
| Mar 31, 2023 | 49.05 Mn |
| Dec 31, 2022 | 53.23 Mn |
| Sep 30, 2022 | 49.04 Mn |
| Jun 30, 2022 | 42.08 Mn |
| Mar 31, 2022 | 41.38 Mn |
| Dec 31, 2021 | 48.28 Mn |
| Sep 30, 2021 | 45.29 Mn |
| Jun 30, 2021 | 37.11 Mn |
| Mar 31, 2021 | 28.95 Mn |
| Dec 31, 2020 | 39.62 Mn |
| Dec 31, 2019 | 19.50 Mn |